SAN DIEGO, April 30, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).Investors who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) prior to October 2022 and continue to hold any of thoseNYSE: ATNM shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.On March 27, 2025, aNYSE: ATNM investor filed a lawsuit agai ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/actinium-law ...

Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Summary by Sections Class Action Details - The lawsuit aims to recover losses for investors who were misled by false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - The complaint highlights that additional analyses provided to the FDA to support the Sierra trial's poor overall survival data were also unlikely to satisfy FDA requirements [2]. - As a result of these issues, the FDA was expected to refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. - Defendants' positive statements about the company's business and prospects were deemed materially misleading [2]. Next Steps for Investors - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=145068&from=3 CLASS PERIOD: Octobe ...

Core Insights - Actinium Pharmaceuticals has presented promising preclinical results for ATNM-400, a novel targeted radiotherapy for prostate cancer, indicating its potential as a transformative treatment option for patients with unmet clinical needs following Pluvicto therapy [1][7] Group 1: Efficacy and Mechanism - ATNM-400 demonstrated a 99.8% tumor growth inhibition with a single 40 µCi/kg dose in prostate cancer models, outperforming Pluvicto [1][6] - In vivo studies showed a statistically significant (p < 0.0001) reduction in tumor volume in 22Rv1 prostate cancer models, highlighting its transformative therapeutic potential [2][5] - The drug exhibited robust antitumor activity in mice with Pluvicto-resistant tumors, administered 14 days post-Pluvicto treatment [3][6] Group 2: Targeting and Safety - ATNM-400 targets a distinct non-PSMA receptor that is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), maintaining expression levels even after Pluvicto treatment [4][7] - The Ac-225 isotope used in ATNM-400 is more potent than Lu-177, capable of causing lethal double-stranded DNA breaks, and has a shorter path length, potentially resulting in fewer off-target effects [4][10] - ATNM-400 was well tolerated in studies, showing no apparent toxicities and efficient clearance from essential organs [10] Group 3: Market Context and Future Outlook - Pluvicto, marketed by Novartis, generated sales of $1.39 billion in 2024, indicating a significant market for prostate cancer therapies [1] - The company anticipates increased demand for therapies addressing patients who progress after Pluvicto, especially following its recent approval in earlier treatment settings [7] - Actinium is committed to advancing ATNM-400's development, with additional data expected later this year [7]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit related to misleading statements and omissions concerning the company's Iomab-B BLA application to the FDA [1][2]. Group 1: Allegations - The complaint alleges that during the class period from October 31, 2022, to August 2, 2024, the defendants made materially false and misleading statements regarding the company's Phase 3 Sierra trial data [2]. - It is claimed that the data from the Sierra trial was unlikely to meet FDA guidelines for the acceptance and approval of the Iomab-B BLA [2]. - The additional analyses provided to the FDA, which suggested improved Overall Survival, were also unlikely to satisfy FDA requirements [2]. - As a result of these issues, the FDA was expected to refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. - The defendants' positive statements about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of ATNM during the specified class period are encouraged to register for the class action by May 27, 2025 [3]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in this class action [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Iomab-B BLA application and its clinical trial data [3][5]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [3]. Group 2: Allegations Against Actinium - The complaint alleges that Actinium and its executives made false or misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA based on the Sierra Trial data [5]. - It is claimed that the additional analyses provided to the FDA were unlikely to satisfy the agency's guidelines, which could lead to a refusal to review or approve the BLA [5]. Group 3: Stock Price Impact - Following the release of a press statement on August 5, 2024, which indicated the need for an additional clinical trial, Actinium's stock price fell by $3.69, or nearly 60%, closing at $2.48 [6][7].

NEW YORK, April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-s ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=144420&from=3 CLASS PERIOD: Octobe ...

NEW YORK  , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit ...